Johnson & Johnson (NYSE:JNJ) Faces a Potential Downside According to Barclays Despite Pharmaceutical Advancements

• Barclays sets a price target of $197 for Johnson & Johnson (NYSE:JNJ), suggesting a potential downside of about -4.06%.
• The European Commission approves IMAAVY® (nipocalimab) for treating generalized myasthenia gravis (gMG), marking a significant advancement in JNJ's pharmaceutical division.
• Despite a recent decrease in stock price, JNJ's market capitalization stands at approximately $494.72 billion, with significant volatility observed over the past year.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company known for its pharmaceuticals, medical devices, and consumer health products. On December 2, 2025, Barclays set a price target of $197 for JNJ, while the stock was trading at $205.34. This suggests a potential downside of about -4.06% from the target price.

Despite the price target set by Barclays, Johnson & Johnson has made significant strides in its pharmaceutical division. The European Commission recently approved IMAAVY® (nipocalimab) for treating generalized myasthenia gravis (gMG). This approval marks a major advancement, as nipocalimab is the first FcRn blocker approved for both adult and adolescent patients aged 12 and older.

In pivotal studies, nipocalimab showed a rapid and substantial reduction in immunoglobulin G levels, a root cause of gMG. Patients experienced up to 20 months of sustained disease control and symptom relief. This approval allows nipocalimab to be used as an add-on to standard therapy, offering new hope for those suffering from this chronic disease.

Currently, JNJ is priced at $205.34, reflecting a decrease of approximately 0.76% with a change of -$1.58. The stock has fluctuated between a low of $205.34 and a high of $207.67 today. Over the past year, JNJ has reached a high of $207.81 and a low of $140.68, indicating significant volatility.

Johnson & Johnson's market capitalization is approximately $494.72 billion, with a trading volume of 8,365,431 shares. Despite the recent price target, the company's advancements in pharmaceuticals, such as the approval of nipocalimab, may influence future stock performance.